Tizanidine Tablet
Product Images NDC 70518-3112

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Tizanidine (NDC 70518-3112). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Remedy_label (Remedy Label)
tiZANidine is a prescription medication manufactured by Dr. Reddy's in Shreveport, LA 71108. The NDC number for the product is 70518-3112-00, and it is only available with a prescription. The package insert contains directions for use, and medication should be stored between 20-26°C (63-77°F) with short excursions permitted to 15-30°C (59-86°F). The product has been repackaged by RemedyRepack Inc. in Indiana, PA 15701. It's important to keep this and all medication out of the reach of children.*
FDA Label Image

Fig1 (Fig1)

Fig1 (Fig1)
This text describes a chart that shows the concentration of Tzanidine in plasma in ng/mL at different hours after dosing. The dosing is done via tablets or capsules of 4mg of Tzanidine, with or without food. Specific codes are assigned to each dosing method. The origin of the chart may come from a company named "Eoiir Mamar RAS Nemar JRes! BN BA% Rak Gar azwaa".*
FDA Label Image

Fig2 (Fig2)

Fig2 (Fig2)
The text describes a graph or chart that shows the effect of 16 mg tizanidine on the Improvement in Ashworth score over time, compared to a placebo, in hours post-dose.*
FDA Label Image

Fig3 (Fig3)

Fig3 (Fig3)
The text describes a study evaluating the effectiveness of zanidine on patients, measuring the improvement in Ashworth score. The study observed patients over a period of 7 weeks with a mean dose of zanidine being 28.6 mg. The improvement was measured at week 3 and the end of maintenance endpoint.*
FDA Label Image

Structure (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.